Lisdexamfetamine
drugOn this page
Also known as L-lysine-dextroamphetamineLisdexamphetamineLisdexanfetamina
Summary
Lisdexamfetamine (CHEMBL1201222) is an approved small molecule (ATC N06BA12); indicated across 8 conditions including attention deficit-hyperactivity disorder and eating disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: N06BA12
- Indications: 8 conditions
- Clinical trials: 34
- Chemistry: 263.38 Da · C15H25N3O
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201222 |
| Name | Lisdexamfetamine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 11597698 |
| ATC | N06BA12 |
| Molecular formula | C15H25N3O |
| Molecular weight | 263.38 |
| InChIKey | VOBHXZCDAVEXEY-JSGCOSHPSA-N |
SMILES: C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N
IUPAC name: (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
Also known as: L-lysine-dextroamphetamine, Lisdexamfetamine, Lisdexamphetamine, Lisdexanfetamina, LISDEXAMFETAMINE
Parent form; salt/anhydrous children: CHEMBL1201178
Patent coverage: 845 distinct patent families (3,199 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| attention deficit-hyperactivity disorder | 4 | MONDO:0007743 | EFO:0003888 |
| eating disorder | 3 | MONDO:0005451 | EFO:0005203 |
| depressive disorder | 3 | MONDO:0002050 | MONDO:0002050 |
| bipolar disorder | 3 | MONDO:0004985 | MONDO:0004985 |
| cocaine dependence | 2 | MONDO:0005186 | EFO:0002610 |
| multiple sclerosis | 2 | MONDO:0005301 | MONDO:0005301 |
| substance-related disorder | 2 | MONDO:0002494 | MONDO:0004938 |
| methamphetamine dependence | 1 | MONDO:0005419 | EFO:0004701 |
Clinical trials
Total trials: 34.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 10 |
| PHASE1 | 7 |
| Not specified | 7 |
| PHASE2 | 6 |
| PHASE3 | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00753012 | PHASE4 | COMPLETED | Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults |
| NCT01051440 | PHASE4 | TERMINATED | Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression |
| NCT01127607 | PHASE4 | COMPLETED | Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance? |
| NCT01324024 | PHASE4 | COMPLETED | Attention & Memory Impairments in Menopausal Women |
| NCT01924429 | PHASE4 | COMPLETED | Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation |
| NCT01977625 | PHASE4 | COMPLETED | LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women |
| NCT02170298 | PHASE4 | TERMINATED | Lisdexamfetamine’s Effect In ADHD in the Brain and Cognition |
| NCT02712996 | PHASE4 | COMPLETED | Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children |
| NCT03070509 | PHASE4 | UNKNOWN | Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients |
| NCT03187353 | PHASE4 | COMPLETED | IMProving Executive Function Study |
| NCT01090713 | PHASE3 | COMPLETED | Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder |
| NCT01093963 | PHASE3 | TERMINATED | Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression |
| NCT01131559 | PHASE3 | TERMINATED | Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression |
| NCT05957055 | PHASE2 | RECRUITING | Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes |
| NCT00958282 | PHASE2 | COMPLETED | Treatment of Cocaine Dependence With Lisdexamfetamine |
| NCT01486810 | PHASE1/PHASE2 | COMPLETED | Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence |
| NCT01615887 | PHASE2 | COMPLETED | Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis |
| NCT01714310 | PHASE2 | COMPLETED | Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation |
| NCT02635035 | PHASE2 | COMPLETED | Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT |
| NCT02659488 | PHASE2 | UNKNOWN | Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects |
| NCT00776555 | PHASE1 | TERMINATED | Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution |
| NCT01490216 | PHASE1 | TERMINATED | Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence |
| NCT02034201 | PHASE1 | COMPLETED | Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence |
| NCT02144415 | PHASE1 | COMPLETED | A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users |
| NCT02668926 | PHASE1 | COMPLETED | Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine. |
| NCT07098585 | PHASE1 | COMPLETED | To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions. |
| NCT07314333 | PHASE1 | COMPLETED | A Trial to Assess How Centanafadine Interacts With Stimulants in the Body |
| NCT01415440 | Not specified | COMPLETED | Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD |
| NCT01986764 | Not specified | WITHDRAWN | E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy |
| NCT01986777 | Not specified | WITHDRAWN | LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy |
| NCT02136147 | Not specified | COMPLETED | ADHD Medication and Predictors of Treatment Outcome |
| NCT02259517 | Not specified | TERMINATED | An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD |
| NCT04132557 | Not specified | COMPLETED | A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine |
| NCT04727476 | Not specified | UNKNOWN | The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).